Innovation Achievements - Sunshine Lake Pharma Co., Ltd.

R&D Ecosystem Innovation Achievements Artificial Intelligence

R&D Innovation

R&D Ecosystem Innovation Achievements Artificial Intelligence

R&D Pipeline

Therapeutic Areas

Drug Name

Modality

Target

Indications

Pre-clinical

Phase I

Phase II

Phase III

NDA Submitted

Launch

Therapeutic Areas	Drug Name	Modality	Target	Indications	Pre-clinical	Phase I	Phase II	Phase III	NDA Submitted	Launch
Infectious Diseases	Dongwei’en (Emitasvir Phosphate)	NCE	NS5A	Hepatitis C
Dong’antai (Netanasvir Phosphate)*	NCE	NS5A	Hepatitis C
Dong’anqiang (Encofosbuvir)*	NCE	NS5B	Hepatitis C
Dong’andi (Morphothiadine Mesylate)	NCE	HBV capsid	Hepatitis B
Dong’anrui (Freethiadine)	NCE	HBV capsid	Hepatitis B
HECN30227	NCE	HBV RNA	Hepatitis B
HEC191834	NCE	TLR8	Hepatitis B
Chronic Diseases	Dongjiantang (Olorigliflozin)	NCE	SGLT-2	Diabetes
Guangjianyou (Insulin glargine (U.S.))	biosimilar	IR	Diabetes
HEC88473	NCE	GLP-1/ FGF21	Diabetes, Obesity, NASH
Dongjiandi (Yinfenidone Hydrochloride)	NCE	-	IPF
HEC53856	NCE	HIF- PHD	Renal anemia
Dongtongshen (Mitizodone Phosphate)	NCE	5-HT, 5-HT1a, 5-HT1b	Depression
HEC95468	NCE	SGC	PAH
HEC93077	NCE	XO/ URAT1	Gout
HEC96719	NCE	FXR	NASH
HEC169584	NCE	THR-β	NASH
HEC137076	NCE	5-HT1f	Migraine
Amlodipine Besylate Granules	Improved new drug	CCB	Hypertension, Coronary heart disease
HECB1502201	Improved new drug	P-CABs	Peptic ulcer bleeding
HECB1701301	Improved new drug	NMDA	AD
Oncology	Dongningchun (Clifutinib Besylate)	NCE	FLT3	AML
Dongningguan (Larotinib Mesylate)	NCE	EGFR	ESCC
HEC53856	NCE	HIF- PHD	CIA
HEC169096	NCE	RET	Tumors
HEC201625	NCE	PD-L1	Tumors

Overseas Clinical Programs Filed/Initiated

Licensing/Transfer/Co-Development

Research Project Sponsorship

The company undertakes R&D for over twenty national "Major New Drug Innovation" projects and supports dozens of research initiatives for national and local governments.

Patent Applications

2400 +

Total Patent Applications Filed

350

PCT Applications

1200 +

Total Granted Patents Worldwide

The innovative drug project Emitasvir Phosphate was awarded the First Prize in the 2023 China (Xiaoshan) Biopharmaceutical High-Value Patent Cultivation Competition
Silver Award in the 2020 Guangdong-Hong Kong-Macao Greater Bay Area High-Value Patent Cultivation and Layout Competition
First recognized as National Intellectual Property Model Enterprise in 2017